公开(公告)号：US20230125803A1

公开(公告)日：2023-04-27

申请号：US17894412

申请日：2022-08-24

申请人： Enanta Pharmaceuticals, Inc.

发明人： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D491/052 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220227746A1

公开(公告)日：2022-07-21

申请号：US17574718

申请日：2022-01-13

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D413/14 ,  A61P31/14 ,  C07D417/14

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10851115B2

公开(公告)日：2020-12-01

申请号：US16023363

申请日：2018-06-29

申请人： Enanta Pharmaceuticals, Inc.

发明人： In Jong Kim ,  Joseph Panarese ,  Thomas P. Blaisdell ,  Jianming Yu ,  Brian C. Shook ,  Yat Sun Or

IPC分类号： C07D519/00 ,  A61P31/16

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20200223867A1

公开(公告)日：2020-07-16

申请号：US16739312

申请日：2020-01-10

申请人： Enanta Pharmaceuticals, Inc.

发明人： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC分类号： C07D513/04 ,  A61K31/56 ,  A61K31/58 ,  A61K31/5513 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10647711B2

公开(公告)日：2020-05-12

申请号：US16188988

申请日：2018-11-13

申请人： Enanta Pharmaceuticals, Inc.

发明人： Thomas P. Blaisdell ,  Brian C. Shook ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D417/14 ,  C07D413/14 ,  A61P31/14 ,  C07D223/16 ,  A61P11/00 ,  C07D413/12

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20160130304A1

公开(公告)日：2016-05-12

申请号：US14931384

申请日：2015-11-03

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07K7/52 ,  A61K45/06 ,  A61K38/13

CPC分类号： A61K45/06 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

摘要： The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US09221878B2

公开(公告)日：2015-12-29

申请号：US14469403

申请日：2014-08-26

申请人： Enanta Pharmaceuticals, Inc.

发明人： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  In Jong Kim

IPC分类号： C07K7/64 ,  A61K38/13 ,  A61K45/06 ,  A61K38/21 ,  A61K38/00

CPC分类号： A61K38/13 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

摘要： The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

摘要翻译： 本发明涉及具有抗HCV的抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地说，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US08927739B2

公开(公告)日：2015-01-06

申请号：US14082406

申请日：2013-11-18

申请人： Enanta Pharmaceuticals, Inc.

发明人： Yao-Ling Qiu ,  Xiaowen Peng ,  In Jong Kim ,  Hui Cao ,  Datong Tang ,  Yat Sun Or ,  Guoqiang Wang ,  Guoyou Xu

IPC分类号： C07D209/54

CPC分类号： C07D209/54

摘要： The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic):

摘要翻译： 本发明一般涉及一种制备5-氮杂螺[2.4]庚烷-6-羧酸及其衍生物的改进方法，其在合成生物活性分子中是有用的中间体，特别是在合成肝素C病毒NS5A抑制剂 。 特别地，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的方法和中间体：

公开(公告)号：US20130165641A1

公开(公告)日：2013-06-27

申请号：US13684927

申请日：2012-11-26

申请人： Enanta Pharmaceuticals, Inc.

发明人： In Jong Kim ,  Tongzhu Liu ,  Jiang Long ,  Guoqiang Wang ,  Yao-Ling Qiu ,  Heejin Kim ,  Yanchun Wang ,  Ly Tam Phan ,  Yat Sun Or

IPC分类号： C07H17/08

CPC分类号： C07D493/08 ,  C07F9/65586 ,  C07H17/08

摘要： The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

公开(公告)号：US20230087410A1

公开(公告)日：2023-03-23

申请号：US17735258

申请日：2022-05-03

申请人： Enanta Pharmaceuticals, Inc.

发明人： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph D. Panarese ,  Yat Sun Or

IPC分类号： C07D513/04 ,  A61K45/06 ,  C07D495/04 ,  A61K31/56 ,  C07D498/08 ,  C07D413/14 ,  C07D413/12 ,  A61K31/58 ,  C07D243/16 ,  C07D471/08 ,  C07D491/048 ,  A61K31/5513 ,  C07D417/14

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.